Blagosklonny works at the Roswell Park Cancer Institute as a professor of oncology, where he has been working since April 15, 2009. At Roswell Park Cancer Institute, the experts usually share ideas as well as possible approaches to curbing cancer. The Tissue-Specific therapy of cancer and cancer prevention by slowing aging are among the ideas that experts at Roswell put their focus. His extensive knowledge in aging and cancer comes in handy at the Institute.
A scientist who focuses on cancer and aging, Mikhail Blagosklonny earned his MD in Internal Medicine from the First Pavlov State of Medical University, St. Petersburg. He is also a holder of Ph.D. in Experimental Medicine and Cardiology from the same University. He became the associate professor of medicine in 2002, at New York Medical College, located in Valhalla, NY. Later on, he moved to Ordway Research Institute where he took up the role of a Senior Scientist.
He has excelled as a professor thanks to the extensive experience he has obtained from the different capacities he has served. His research interest includes the underlying mechanisms of aging (known as biogerontology), cancer, anti-aging drugs, as well as targeted cancer therapies that are responsible for guarding the healthy cells against potential damage.
Mikhail Blagosklonny authored the aging hyperfunction theory, and also writes about chemotherapeutic and cyclotherapy engineering. However, he has become popular because of his keen interest in oncology. He has a strong belief that it is possible to control aging and cancer and that cancer is curable – explaining why he recommended the use of Rapamycin. He is a great author having written more than 300 research articles, reviews, and book chapters, and are all published under his name. At PLOS ONE, International Journal of Cancer, and the American Journal of Pathology, Mikhail Blagosklonny serves as the associate editor. View Mikhail’s profile in LinkedIn
Blagosklonny is not only hard working but also, he is known to exhibit commitment in everything that he puts his mind into. These two critical virtues have significantly contributed to what he has achieved as one of the leading oncology researchers in the world. He has a deep love for humanity, and the great vision of participating in the delivery of a disease-free world – and this is what he inspired his career choice.